Diabetes

Diabetes-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Systems and methods of diabetes management
May 25, 2017 - N°20170147769

Presented herein are one or more software applications to help a user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with an analyte measurement device.
NEW Glp-1 derivatives
May 25, 2017 - N°20170145069

The invention relates to a derivative of a glp-1 peptide, which peptide has two lys residues, namely a first and a second lys residue, and a maximum of eight amino acid changes as compared to glp-1(7-37) (seq id no: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second lys residue, respectively, ...
NEW Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof
May 25, 2017 - N°20170145000

The present invention relates to canagliflozin monohydrate and its crystalline forms. Compared to the prior art, canagliflozin monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability. The present invention also relates to preparation methods of canagliflozin monohydrate and its crystalline forms, ...
NEW Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Velocity-weighting model predictive control of an artificial pancreas for type 1 diabetes applications
May 25, 2017 - N°20170143899

Methods, devices, algorithms, and systems controlling insulin delivery employ velocity-weighting. Predicted glucose outcomes are penalized with a cost modulated by a factor that is a function of the glucose velocity, wherein glucose outcomes are penalized increasingly less for increasingly negative glucose velocities, when glucose level is high, and/or wherein a hyperglycemic glucose value that is already converging to the ...
NEW Rituximab induction therapy followed by glatiramer acetate therapy
May 25, 2017 - N°20170143824

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The ...
NEW Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
May 25, 2017 - N°20170143802

The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analogue conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to ...
NEW Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Calcitonin mimetics for treating diseases and disorders
May 25, 2017 - N°20170143800

Calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues ...
NEW Modulation of cellular stress
May 25, 2017 - N°20170143798

Disclosed are compositions and methods for modulating oxidative and/or endoplasmic reticulum (oer) stress. More particularly, the present invention discloses compositions and methods that target oer stress inhibitors to pancreatic cells for treating diseases associated with oxidative and/or oer stress, including metabolic disorders such as diabetes.
NEW Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
May 25, 2017 - N°20170143779

The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an aav virion comprising an aav vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are aav vectors and aav ...
NEW Calcium folate (cafolate) and therapeutic methods based thereon
May 25, 2017 - N°20170143720

Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as hepatitis b virus infection, tuberculosis and type 2 diabetes based upon the administration of cafolate. In one embodiment is a method of treating cancer comprising administration of cafolate. In another embodiment is a method of treatment inflammatory-based disease and disorders comprising administration of cafolate.
NEW Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
May 25, 2017 - N°20170143667

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ...
NEW Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
May 25, 2017 - N°20170143666

Provided are compositions comprising compounds or precursors to compounds which may be used for a. Variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ...
NEW Effect of lipophilic nutrients on diabetic eye diseases
May 25, 2017 - N°20170143646

Compositions containing molecular dispersions of lipophilic nutrients and methods thereof are provided for delaying the development and maturation of eye related complications of diabetes by administering a composition containing lipophilic nutrients. More particularly, methods relate to delaying the development and maturation of eye related complications of diabetes by administering a composition containing lutein and its isomers, lutein ester, zeaxanthin isomers, ...
NEW Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Apoiii and the treatment and diagnosis of diabetes
Biocrine Ab
May 18, 2017 - N°20170138968

The present invention provides methods of identifying candidate compounds for the treatment of type i diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein ciii (“apociii”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apociii-induced increase in intracellular ...
Organic compositions to treat apoc3-related diseases
Arrowhead Pharmaceuticals, Inc.
May 18, 2017 - N°20170137814

The present disclosure relates to compositions and methods for treating apoc3-related diseases such as: hypertriglyceridemia (e. G., type v hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a rnai agent to apoc3.
Compositions and methods for treating diabetes
The Children's Medical Center Corporation
May 18, 2017 - N°20170137800

Compositions containing an fkbp 11 peptide (i. E., fkbp11 polypeptide, a variant or a fragment thereof), a fusion protein containing an fkbp11 peptide, or a nucleic acid encoding an fkbp 11 peptide are disclosed. Also disclosed are methods of reducing blood glucose levels, improving glucose tolerance, decreasing hepatic gluconeogenic activity and/or improving insulin sensitivity in a subject, by administering a composition ...
Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof
Affiris Ag
May 18, 2017 - N°20170137509

The present invention provides monoclonal antibodies specific for one or more truncated variants of human osteopontin and vaccines comprising at least one isolated osteopontin peptide, as well methods for manufacturing said antibodies and vaccines. Furthermore, a diagnostic method making use of said antibodies is provided. Said antibodies and vaccines are used in therapy, especially in treatment and/or prevention of ...
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
Aveo Pharmaceuticals, Inc.
May 18, 2017 - N°20170137506

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use ...
Long-acting single-chain insulin analogues
Case Western Reserve University
May 18, 2017 - N°20170137488

A single-chain insulin analogue containing a basic side chain at position a8 (arginine, histidine, lysine, or ornithine), a basic side chain at position b29 (arginine, histidine, lysine, or ornithine), and a foreshortened c-domain of length 6-11 residues is provided. Residues c1 and c2 of the c-domain have a net negative charge of −1 or −2; c3 is chosen from a ...
Peptide yy (pyy) analogues
Imperial Innovations Limited
May 18, 2017 - N°20170137486

Analogues of peptide yy (pyy), which are useful in treating disorders such as diabetes and obesity and also for inducing cosmetic weight loss, related compositions, formulations, uses and methods.
Insulin-containing prolonged-action preparation
Obschestvo S Ogranchennoj Otvetctvennostu "biosabtek"
May 18, 2017 - N°20170136096

The invention relates to the field of biotechnology and medicine, and specifically to insulin-containing injectable formulations used, in particular, for treating diabetes mellitus. The present formulation comprises insulin and a pharmacologically acceptable polymer having a hydrodynamic diameter of more than 4. 5+/−0. 5 nanometers. As said polymer, at least one polymer having a molecular weight of 20-70 kda may be optimally used, ...